Skip Navigation



QJM Advance Access published online on February 5, 2008
QJM, doi:10.1093/qjmed/hcm148
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
101/4/261    most recent
hcm148v2
hcm148v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Henriksen, P. A.
Right arrow Articles by Boon, N. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Henriksen, P. A.
Right arrow Articles by Boon, N. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the Association of Physicians. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Management of upper gastrointestinal haemorrhage complicating dual anti-platelet therapy

Peter A. Henriksen1, Kelvin Palmer2 and Nick A. Boon1

From the 1Consultant Cardiologist, Department of Cardiology, Western General Hospital, Edinburgh, EH42XY, UK and 2Department of Gastroenterology, Western General Hospital, Edinburgh, EH42XU, UK

Address correspondence to Dr P.A. Henriksen, Consultant Cardiologist, Department of Cardiology, Western General Hospital, Edinburgh, EH42XY, UK. email: p.henriksen{at}blueyonder.co.uk

Received 25 March 2007 and in revised form 1 July 2007


  Abstract

Upper gastrointestinal haemorrhage is a serious complication of aspirin and clopidogrel (dual) anti-platelet therapy with a high morbidity and mortality. Using an illustrative case this article examines the prognostic significance of gastrointestinal haemorrhage and the risk of stopping anti-platelet therapy. The management of this clinical challenge is reviewed, in the absence of a clinical guideline, with particular reference to the judicious tailoring of anti-platelet therapy, the role of therapeutic endoscopy and the utility of blood transfusion.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.